XZJ Biotech Secures Dual Recognition on Hurun Global Cheetahs Index 2024 and Hurun China Under40s 2024 Ahead of IPO Filing

Recently, Hurun Research Institute, which provides the world's largest unicorn and future unicorn rankings, released two major annual lists for 2024 –– targeting startups for evaluation."2024 Hurun Global Gazelle Companies List"And for the evaluation of entrepreneurs"2024 Hurun U40 China Entrepreneurial Pioneer", Xbiome is always on the list.

On December 18, Dr. Tan Yan, co-founder and CEO of Xbiome, was invited as a representative of the winning companies to attend the 2024 Hurun Global Cheetah Companies Conference. During the roundtable dialogue session on "How 'AI+' Empowers New Quality Productivity," he introduced Xbiome's AI microbiome research and industrial transformation platform, as well as its achievements in pharmaceutical research and industrialization.

[December 18, Guangzhou]Hurun Research Institute and Guangzhou Nansha Jointly Release Hurun Future Unicorn Series — "Hurun Global Cheetahs Index 2024". The list identifies high-growth companies founded after 2000 that are most likely to reach a unicorn valuation of one billion US dollars within five years. This is the second release of the "Hurun Global Cheetahs Index" by the Hurun Research Institute.

The organizer introduced that the Hurun Research Institute referred to a large amount of information provided by world-top investment institutions, and repeatedly verified with professional investment databases, industry experts, media sources, and founders of Cheetah companies. Finally, 928 Cheetah companies were identified globally. Xbiome, as a representative of China's gut microbiome research, pharmaceuticals, and health enterprises, successfully made the list.

This year, global Cheetah enterprises are distributed across 37 countries and 243 cities, increasing by 181 companies from last year, marking a 24% growth. The organizer stated that among this year's Cheetah enterprises,Biotechnology (144) and Health Technology (123)It is the main business area of Hurun Cheetah enterprises, fully reflecting the current entrepreneurial trend.Making healthcare the industry most impacted by Cheetah enterprises.

In the past year, China has added more than 70 Cheetah companies, including Xbiome, mainly concentrated in the fields of biotechnology, health technology, robotics, semiconductors, and new energy. The Guangdong-Hong Kong-Macao Greater Bay Area, where Xbiome is located, hosts a total of 68 Cheetah companies, surpassing the combined total of the UK and France.

Rupert Hoogewerf, Chairman and Chief Research Officer of Hurun Report, spoke highly of the listed companies: "Hurun Gazelles are the most exciting companies in the world and the fastest-growing startups globally. As an investor, it is crucial to find the best venture capital firms to invest in these Hurun Gazelles. As a local government, efforts should be made to attract these companies to establish themselves locally; otherwise, there is a risk of falling behind. As a world-leading company, collaboration with them is essential, or else there is a risk of being left behind."

The "2024 Hurun Global Cheetah Enterprises Conference" held on the same day in Nansha, Guangzhou, invited over a hundred guests to exchange and share insights, focusing on cheetah enterprises and start-ups, future industry trends, ecosystem development, analyzing industrial dynamics, and exploring how new technologies empower industrial growth.Dr. Tan Yan, Co-founder and CEO of Xbiome, was invited to share insights at the roundtable discussion titled "How 'AI+' Empowers New Quality Productivity."

Dr. Tan Yan introduced that, over the past seven years since its establishment, Xbiome has independently built and continuously improved an AI microbiome research and product development platform. Centered around this technological platform, the company has developed three main business areas: drug research, FMT fecal microbiota transplantation therapy, and probiotic development. Xbiome widely applies artificial intelligence in various aspects of both front-end and back-end operations, including drug discovery, product development, and donor-patient matching. It is committed to providing innovative gut microbiome drugs and probiotics for patients with diseases and sub-healthy populations, as well as more precise and clinically valuable FMT fecal microbiota transplantation treatments.

During the entrepreneurial process, Xbiome has built a multidisciplinary scientific team with an AI+BT background, integrating AI into the entire chain from science to industry, making cutting-edge technology accessible to patients and consumers. Dr. Tan Yan stated that Xbiome's AI microbiome research and product development platform is advanced, comprehensive, and highly open, empowering upstream and downstream partners such as pharmaceutical companies, hospitals, research institutions, health organizations, probiotic enterprises, and food companies. This enables them to collaborate with Xbiome in multiple dimensions—academic, clinical, co-development, and commercial licensing—based on their own business needs, thereby upgrading both scientific research and industrial value.

[December 16, Chengdu]Hurun Research Institute Releases "Hurun China Under40s 2024" to Identify Young Entrepreneurial Pioneers in China Aged 40 and Under

Click to view the full list and related reports:

1. Hurun Global Gazelle Companies 2024

2. 2024 Hurun U40 China Entrepreneurial Pioneer

-End-